Navigation Links
Long-term 12-month safety data on ADHD patch DAYTRANA
Date:10/26/2007

BOSTON OCTOBER 25, 2007 Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ), the global specialty biopharmaceutical company, announced that data from a 12-month study of DAYTRANATM (methylphenidate transdermal system), the Attention Deficit Hyperactivity Disorder (ADHD) patch, demonstrated that DAYTRANA provided significant ADHD tolerability and symptom control improvement in children aged 6 to 12 years. The study data was presented today at a major scientific and educational meeting of child and adolescent psychiatrists held in Boston, and is consistent with data previously presented.

In our study, children with ADHD experienced effective ADHD symptom control improvement when using DAYTRANA for 12 months, improving their ability to maintain focus and concentration in and outside of the classroom, reported investigator Frank A. Lpez, M.D., neurodevelopmental pediatrician at the Childrens Developmental Center, Winter Park, Fla. Importantly, this year-long study showed that DAYTRANA maintained a favorable safety profile throughout the study period, with adverse events consistent with previous DAYTRANA studies.

Shires DAYTRANA is the first and only patch medication approved by the U.S. Food and Drug Administration (FDA) to treat the symptoms of ADHD in children aged 6 to 12 years. The study results demonstrate that adverse events associated with DAYTRANA were similar to other methylphenidate products. The most common adverse events reported in this study were decreased appetite, headache, upper respiratory tract infection, cough, fever, and decreased weight. When worn for the recommended nine hours, efficacy has been demonstrated from the first time point measured (two hours) through the 12-hour time point. Because DAYTRANA is a patch, physicians may recommend that patients shorten the wear time if shorter duration of effect is desired or to help manage the potential for late-day side effects, such as lack of appetite or difficulty sleeping
'/>"/>

Contact: Jennifer Anello
212-601-8132
Porter Novelli
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Pancreatitis: Minimially Invasive Procedure Offers Long-Term Pain Relief
2. Long-Term Survival can be Predicted by a Simple Lung Test
3. Small lumps in breast if not treated may cause long-term harm
4. Lung Therapy Found To Have Long-Term Side Effects
5. Long-Term Benefits Of Statins Questioned
6. Long-term use of calcium supplements to prevent colon cancer
7. Survivors of childhood cancer may have long-term health problems
8. Long-term Care Should Be A Planned Affair
9. Pfizer vouches safety of long-term inhaled insulin.
10. Clue to Link Between Obesity and Long-Term Memory Discovered
11. Drug Regulators Need To Think In Long-Term, Say Charities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2008)...ert Pathologists Discuss the Latest Developments i...RTHFIELD, Ill., Sept. 5 /PRNewswire-USNewswire/ --...point. Molecular testing and the promise,of person...reated. Digital,slides and other imaging technolog...lege of American Pathologists is taking a leadersh...
(Date:9/5/2008)...hers explain how theoretical ,anti-cloak, could br...pt. 5 (HealthDay News) -- Just in case someone dev...cientists say they know how to uncloak the objects... Optics Express , certain materials underneath an ...o be seen again. , Researchers at Shanghai Jiao...
(Date:9/5/2008)...HINGTON, Sept. 5 /PRNewswire-USNewswire/ -- Speake...y in support of the aims of the "Stand,Up to Cance... "There is not a person in our country who has no...r kills 565,000 Americans annually, and each,year ...ricans must work,together to make eradicating the ...
(Date:9/5/2008)...HINGTON, Sept. 5 /PRNewswire-USNewswire/ -- U.S. c...r relief to Cuban victims of Hurricane,Gustav, whi...s., (http://www.PanAmericanRelief.org ), "Donatio...perately need,after this natural disaster," says M... Initiative at the Pan American Development Founda...
Breaking Medicine News(10 mins):Health News:Leaders in Pathology Meet in San Diego: Sept. 25 - 28, 2008 2Health News:Cuban Disaster Relief Donations Sought in the Wake of Hurricane Gustav 2
...itis reported at Federation of Clinical Immunology...makes these people susceptible to the disabling in...closed the circle between key genes identified in ... Center for Genomics and Human Genetics at The Fei...
...tle surprises up its sleeves; one of which is a su...g to experts, the spread of dengue, which is trans...c in much of the region, has also accelerated in r... urbanization and travel or migration within the r...
... who was admitted to a hospital in East Delhi afte...aising speculations of a suicide attempt by him, ... a statement to the Delhi Police, Singh said that ...lass window panes broke when he banged his hands o...
...t how the Ice Age in Europe dried up the West Afri...of scientists from the University of California, S...ry of the West African monsoon yet, spanning 155,0...ges. They analysed the amount of barium in plankt...
Other Medicine News:Health News:New Developments in Rheumatoid Arthritis 2Health News:New Developments in Rheumatoid Arthritis 3Health News:Dengue Sweeping Across Southeast Asia 2
(Date:9/3/2008)...s Phase 3 Plans with FDA, PRINCETON, N.J., Sept. ...ced today that it successfully completed two key c... new, innovative low-dose, once-weekly,contracept...rnal product,code AG-200-15. The Phase 2b safety a...point of ovulation suppression, cycle control and ...
(Date:9/3/2008)...trong Evidence Pycnogenol(R) Lowers Joint, Pain, S...lowing Cessation of th... According to the Center for,Disease Control (CDC)...s,is on the rise. A new study published in the Au...nogenol(R), bark extract from the French maritime ...
(Date:9/3/2008)...wswire-FirstCall/ -- A sub-analysis of,the TRITON-...prasugrel,compared with clopidogrel significantly ... (7.4 percent vs. 9.7 percent, p<0.0001), regardle...of an artery-opening,procedure known as percutaneo...d spontaneously during the longer-term maintenance...
(Date:9/2/2008)...-FirstCall/ --, - This Analysis Showed That Multa... 34% in Patients With Atrial Fibrillation or Atria...otic Therapy, The results of a post-hoc analysis ...oday at the clinical trial update session of the E...nich, Germany. Previous results,from the landmark ...
Breaking Medicine Technology:Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 2Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 3Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 4Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis 2Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis 3Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis 4Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel 2Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel 3Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel 4Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel 5Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel 6Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 2Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 3Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 4Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 5Sinexus Welcomes New CEO and Completes Series B 21149 1Sinexus Welcomes New CEO and Completes Series B 21149 2Sinexus Welcomes New CEO and Completes Series B 21149 3Elekta and Mary Bird Perkins Cancer Center Sign Strategic Multi Center Radiation Therapy Systems Agreement 21144 1Elekta and Mary Bird Perkins Cancer Center Sign Strategic Multi Center Radiation Therapy Systems Agreement 21144 2Elekta and Mary Bird Perkins Cancer Center Sign Strategic Multi Center Radiation Therapy Systems Agreement 21144 3Summer is for Sleeping 3F Exhausted Americans Challenged to Sleep in on Longest Day of the Year 21139 1Summer is for Sleeping 3F Exhausted Americans Challenged to Sleep in on Longest Day of the Year 21139 2Summer is for Sleeping 3F Exhausted Americans Challenged to Sleep in on Longest Day of the Year 21139 3Spradling receives Gruber Foundation Genetics Prize for new genetic techniques 3537 1Spradling receives Gruber Foundation Genetics Prize for new genetic techniques 3537 2Spradling receives Gruber Foundation Genetics Prize for new genetic techniques 3537 3Spradling receives Gruber Foundation Genetics Prize for new genetic techniques 3537 4
...zed phase II/III clinical trial,anticipated later ...tCall/ -- Cell,Therapeutics, Inc. (CTI) announced ...nstrate that treatment with pixantrone (BBR,2778) ...ty, while,doxorubicin and mitoxantrone induced sig...cardiac side effects of equiactive doses,of pixant...
...WIRE)--Jun 26, 2007 - Sirtris,Pharmaceuticals, Inc...sed on discovering and developing small molecule d...hat activation of SIRT1, a,member of the sirtuin f...rodegenerative diseases such as Alzheimer,s Diseas...ls. These findings,appear in an article published ...
Other Medicine Technology:Publication on Pixantrone Preclinical Studies Demonstrates Reduced,Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and,Mitoxantrone 2Publication on Pixantrone Preclinical Studies Demonstrates Reduced,Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and,Mitoxantrone 3Publication on Pixantrone Preclinical Studies Demonstrates Reduced,Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and,Mitoxantrone 4Publication on Pixantrone Preclinical Studies Demonstrates Reduced,Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and,Mitoxantrone 5Publication on Pixantrone Preclinical Studies Demonstrates Reduced,Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and,Mitoxantrone 6Resveratrol Studies Suggest Broad Implications for SIRT1 Activation,in Neurodegenerative Diseases of Aging Such as Alzheimer's Disease 2Resveratrol Studies Suggest Broad Implications for SIRT1 Activation,in Neurodegenerative Diseases of Aging Such as Alzheimer's Disease 3
High sensitive, specific one step immunochromatographic assay for human infectious disease
Span Diagnostics Limited
Malaria (P. fal.) Ag Rapid Test
OptiMAL is a malaria test, for diagnosis and therapy control of an infection by Plasmodium species (Malaria).
Medicine Products: